drugset / Trial / NCT04600960
Eltrombopag for Chemotherapy-induced Thrombocytopenia
Phase 2
Recruiting
50 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Henan Cancer Hospital · collabThe Second Affiliated Hospital of Kunming Medical University · collabTianjin Medical University Cancer Institute and Hospital · collabTianjin Medical University Second Hospital · collabTianjin People's Hospital · collabTianjin Third Central Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of eltrombopag to treat chemotherapy-induced thrombocytopenia in solid tumors
Timeline
- Start
- 2020-12-31
- Primary completion
- 2025-03-31
- Completion
- 2025-12-31
Publications
- Background Winer ES, Safran H, Karaszewska B, Richards DA, Hartner L, Forget F, Ramlau R, Kumar K, Mayer B, Johnson BM, Messam CA, Mostafa Kamel Y. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Med. 2015 Jan;4(1):16-26. doi: 10.1002/cam4.326. Epub 2014 Aug 28.
- Background Winer ES, Safran H, Karaszewska B, Bauer S, Khan D, Doerfel S, Burgess P, Kalambakas S, Mostafa Kamel Y, Forget F. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study. Int J Hematol. 2017 Dec;106(6):765-776. doi: 10.1007/s12185-017-2319-9. Epub 2017 Sep 1.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 75 mg | — |